Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Dynavax Technologies Corp. (NASDAQ: DVAX).

Full DD Report for DVAX

You must become a subscriber to view this report.


Recent News from (NASDAQ: DVAX)

Midday Gainers / Losers (05/17/2018)
Gainers: CARV +78% . CPSH +40% . EGY +24% . EIGR +20% . LOXO +18% . BZUN +17% . BDSI +17% . RTTR +16% . ESND +15% . WWE +15% . More news on: Carver Bancorp, Inc., CPS Technologies Corp., VAALCO Energy, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: May, 17 2018 12:40
Healthcare - Top 5 Gainers / Losers as of 12:20 AM (05/17/2018)
Gainers : LOXO +19% . RTTR +18% . SPPI +17% . EIGR +16% . BDSI +15% . More news on: Loxo Oncology, Ritter Pharmaceuticals, Spectrum Pharmaceuticals, Inc., Healthcare stocks news, , Stocks on the move, Read more ...
Source: SeekingAlpha
Date: May, 17 2018 12:21
Dynavax down 13% on SD-101/Keytruda melanoma data
Dynavax ( DVAX -13.4% ) is down on increased volume in early trade in apparent response to the release of updated results from its ongoing Phase 1/2 study of SD-101 + Merck's Keytruda (pembrolizumab) in PD-1-naive advanced melanoma patients. More news on: Dynavax Technologies Co...
Source: SeekingAlpha
Date: May, 17 2018 10:37
Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the 2018 American Society for Clinical Oncology Annual Meeting
Abstract Data Show Overall Response Rate of 60% in 25 Advanced Melanoma Patients Naïve to Anti-PD-1 Therapy Poster Presentation to Include Data from a Total of over 50 Patients and Will Compare SD-101 at Two Dose Levels BERKELEY, Calif., May 16, 2018 (GLOBE NEWSWIRE) -- Dynava...
Source: GlobeNewswire
Date: May, 16 2018 17:15
Biotechs perk up ahead of ASCO abstract drop
The SPDR S&P Biotech ETF ( XBI +1.1% ) is up  1%  as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1 - 5. More news on: SPDR Biotech ETF, Celgene Corporation, bluebird bio, Inc., He...
Source: SeekingAlpha
Date: May, 16 2018 12:56
Market Trends Toward New Normal in Dynavax Technologies, Synergy Resources, Allscripts Healthcare Solutions, Plug Power, GameStop, and Newfield Exploration - Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, May 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dynavax Technologies Corporation (NASDAQ:DVAX), Synergy Resources Corporat...
Source: GlobeNewswire
Date: May, 16 2018 08:30
Biotechs Emerge Unscathed And Ready To Go!
Biotech Pulse Biotechs have a pulse now, and it's beginning to beat a little harder! As President Trump on Friday, May 11, delivered a blueprint, American Patients First , to lower drug prices the early indications appear to be that the biotech and pharmaceutical industries have jumped th...
Source: SeekingAlpha
Date: May, 15 2018 08:28
Dynavax: Valuing Success
Dynavax's (DVAX) newly approved HEPLISAV-B vaccine is just beginning its commercial development. The process is sure to be prolonged, though it appears to be proceeding apace. In this post, I explain my expectation that HEPLISAV-B's ongoing rollout will be successful in targeting peak sales of...
Source: SeekingAlpha
Date: May, 15 2018 02:49
JF's Core Biotech Buys #15: Removal Of A Key Overhang, Buying Weakness In I-O, Updates And Adding To 2 Positions
Welcome to the fifteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size ...
Source: SeekingAlpha
Date: May, 14 2018 11:37
Dynavax Will Not Be Another Synergy
Dynavax Technologies ( DVAX ) has been making solid strides in its efforts to launch Heplisav-B, its novel best-in-class Hepatitis B vaccine, since it won FDA approval last year on the third attempt. We have written research notes in the past reflecting on the challenges of 2017 and celebratin...
Source: SeekingAlpha
Date: May, 11 2018 01:07

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-1313.2513.22513.4512.901,129,769
2018-08-1013.3013.3013.5013.05409,605
2018-08-0913.3513.4013.67513.25542,315
2018-08-0813.6513.3013.7513.25687,968
2018-08-0713.8013.7013.8512.901,440,103

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-13101,826290,96334.9962Cover
2018-08-10105,131164,90063.7544Short
2018-08-0989,323138,24164.6140Short
2018-08-0877,901170,61645.6587Short
2018-08-07205,858443,86446.3786Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on DVAX.


About Dynavax Technologies Corp. (NASDAQ: DVAX)

Logo for Dynavax Technologies Corp. (NASDAQ: DVAX)

Not available

 

Contact Information

 

 

Current Management

  • Dino Dina / President, CEO
  • William J. Dawson / CFO

Current Share Structure

  • Market Cap: $1,165,771,221 - 05/15/2018
  • Issue and Outstanding: 61,681,017 - 03/01/2018

 


Recent Filings from (NASDAQ: DVAX)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 18 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 16 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: March, 22 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: March, 22 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: March, 22 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: March, 22 2018

 

 


Daily Technical Chart for (NASDAQ: DVAX)

Daily Technical Chart for (NASDAQ: DVAX)


Stay tuned for daily updates and more on (NASDAQ: DVAX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: DVAX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in DVAX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of DVAX and does not buy, sell, or trade any shares of DVAX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/